Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022-Reference-Cited by-同舟云学术

Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022

Published:2022-07-28 Issue:30 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Sentís Alexis¹^ORCID,Kislaya Irina²,Nicolay Nathalie³,Meijerink Hinta⁴,Starrfelt Jostein⁴,Martínez-Baz Iván⁵⁶,Castilla Jesús⁵⁶,Nielsen Katrine Finderup⁷,Hansen Christian Holm⁷,Emborg Hanne-Dorthe⁷,Nardone Anthony¹,Derrough Tarik³,Valenciano Marta¹,Nunes Baltazar²,Monge Susana⁸⁹,

Affiliation:

1. Epidemiology Department, Epiconcept, Paris, France

2. Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisbon, Portugal

3. Vaccine preventable diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Solna, Sweden

4. Norwegian Institute of Public Health (NIPH), Oslo, Norway

5. CIBER on Epidemiology and Public Health (CIBERESP), Madrid, Spain

6. Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain

7. Statens Serum Institut (SSI), Copenhagen, Denmark

8. CIBER on Infectious Diseases (CIBERINFEC), Madrid, Spain

9. Instituto de Salud Carlos III (ISCIII), Madrid, Spain

Abstract

By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65–79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference15 articles.

1. European Centre for Disease Prevention and Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. Stockholm: ECDC; 21 Apr 2022. [Accessed 13 Jun 2022]. Available from: https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans

2. European Centre for Disease Prevention and Control (ECDC). Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA. Stockholm: ECDC; 21 Jan 2022. [Accessed 16 Jun 2022]. Available from: https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-omicron-variant-concern-voc-week-2-data-20-january-2022

3. Chapter 10: Analysing data and undertaking meta-analyses. Cochrane Training. [Accessed 13 Jun 2022]. Available from: https://training.cochrane.org/handbook/archive/v6.2/chapter-10#section-10-3

4. European Centre for Disease Prevention and Control (ECDC). Engagement of ECDC in projects funded through the Horizon 2020 call for Pan-European COVID-19 cohorts. Stockholm: ECDC

5. 9 Jun 2020. Available from: https://www.ecdc.europa.eu/en/news-events/engagement-ECDC-projects-funded-through-call-for-Pan-European-COVID-19-cohorts

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023;Eurosurveillance;2024-01-04

2. Monitoring COVID‐19 vaccine effectiveness against COVID‐19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022;Influenza and Other Respiratory Viruses;2023-11

3. Differences in Trends in Admissions and Outcomes among Patients from a Secondary Hospital in Madrid during the COVID-19 Pandemic: A Hospital-Based Epidemiological Analysis (2020–2022);Viruses;2023-07-24

4. COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022;Eurosurveillance;2023-06-29

5. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022;Eurosurveillance;2023-02-02